Alison Taunton-Rigby, PhD, OBE

Taunton-RigbyDirector and Trustee, Healthcare, Life Sciences and Financial Services

Alison Taunton-Rigby has been President and Chief Executive Officer of several public and private companies in the life science and healthcare industries. She currently serves as a Director on a number of public, private, non-profit, ESOP and mutual fund boards. Dr. Taunton-Rigby was Founder, President and Chief Executive Officer of RiboNovix, Inc., a biotechnology company. Prior to this she was President and Chief Executive Officer of Aquila Biopharmaceuticals, Inc., a public life sciences company that was merged in late 2000 with Antigenics Inc. She was also President and Chief Executive Officer of Cambridge Biotech Corporation, where she led the turn-around, re-structuring and emergence from bankruptcy. In addition, she has served as President and Chief Executive Officer of Mitotix Inc., now merged with GPC Biotech. Previous to this position, she was Senior Vice President, Biotherapeutics, at Genzyme Corporation, where she had overall responsibility for Genzyme's biotherapeutics division. Dr. Taunton-Rigby has also served in senior management positions at ADL Inc., Vivotech Inc., Biogen, Inc. and Collaborative Research, Inc.

Dr. Taunton-Rigby received her doctorate from the University of Bristol in England, and is a graduate of the Advanced Management Program of the Harvard Business School. She is a Director of Columbia Funds, Healthways, Inc., Abt Associates, Inc., ICI Mutual Insurance Company, and Boston Children's Hospital. In addition, she is a director of the Massachusetts Women's Forum, and a Director Emeritus of the Biomedical Science Careers Program. Dr. Taunton-Rigby is a member of the Business Advisory Council, Simmons College, School of Management, and of the Health Policy & Management Advisory Board, Boston University School of Public Health, an Advisor to Civic Capital LLC, and a former Director and Chair of the Massachusetts Biotechnology Council (MBC) and of the Biotechnology Industry Organization (BIO), where she chaired the Emerging Companies Section.

In 2005, she was appointed by the Governor to the Massachusetts Biomedical Research Advisory Committee (stem cell research) and in 2008 to the Scientific Advisory Board, Massachusetts Life Science Center. In 2002, Dr. Taunton-Rigby was awarded the OBE (Officer of the Order of the British Empire) by Queen Elizabeth II for her work as a leader in the research, development and promotion of biotechnology. In 2009, she was awarded an honorary D.Sc. by the University of Bristol, UK.

Dr. Taunton-Rigby has served as a Director on seven public companies, and numerous private and non-profit organizations. She is or has been a member of Compensation, Audit, Nominating and Governance, and Strategic Planning committees. At Boston Children’s Hospital, she chairs the Patient Care Assessment Committee.